for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aytu Bioscience Inc

AYTU.OQ

Latest Trade

1.19USD

Change

-0.04(-3.25%)

Volume

15,300

Today's Range

1.15

 - 

1.23

52 Week Range

0.69

 - 

2.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.23
Open
1.20
Volume
15,300
3M AVG Volume
2.98
Today's High
1.23
Today's Low
1.15
52 Week High
2.60
52 Week Low
0.69
Shares Out (MIL)
17.69
Market Cap (MIL)
21.76
Forward P/E
-1.44
Dividend (Yield %)
--

Next Event

Q1 2020 Aytu BioScience Inc Earnings Release

Latest Developments

More

Cerecor To Sell Pediatric Portfolio To AYTU Bioscience

Aytu Bioscience Announces Definitive Agreement To Acquire Innovus Pharmaceuticals

Aytu Bioscience Inc Reports 291% Revenue Growth In Q3 FY19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aytu Bioscience Inc

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.

Industry

Biotechnology & Drugs

Contact Info

373 Inverness Pkwy Ste 206

+1.720.4376580

http://aytubio.com/

Executive Leadership

Joshua R. Disbrow

Chairman of the Board, Chief Executive Officer

David A. Green

Chief Financial Officer, Treasurer, Secretary

Jarrett T. Disbrow

Chief Operating Officer

Steven J. Boyd

Independent Director

Gary V. Cantrell

Independent Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-966.000

2019

-2.220

2020(E)

-0.795
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.97
Price To Book (MRQ)
3.04
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-115.42
Return on Equity (TTM)
-97.28

Latest News

Latest News

BRIEF-Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2

* BIGGER CAPITAL FUND L P REPORTS A 7.4 PERCENT PASSIVE STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 2 - SEC FILING Source text: (http://bit.ly/2HiWvi8) Further company coverage:

BRIEF-Aytu Bioscience Gets Market Registration For The Mioxsys System For Male Infertility In Mexico

* AYTU BIOSCIENCE RECEIVES MARKET REGISTRATION FOR THE MIOXSYS® SYSTEM FOR MALE INFERTILITY IN MEXICO Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Announces Pricing Of $12 Mln Public Offering

* AYTU BIOSCIENCE ANNOUNCES PRICING OF $12,000,000 PUBLIC OFFERING

BRIEF-Aytu BioScience Provides Update On The Continued Growth Of Natesto In The U.S.

* AYTU BIOSCIENCE PROVIDES UPDATE ON THE CONTINUED GROWTH OF NATESTO® IN THE U.S. Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Q2 Revenue $1.1 Mln, An Increase Of 32 pct

* AYTU BIOSCIENCE INC - TOTAL REVENUE FOR Q2 WAS ABOUT $1.1 MILLION, AN INCREASE OF 32%

BRIEF-Aytu Bioscience Appoints David Green As CFO

* AYTU BIOSCIENCE ANNOUNCES APPOINTMENT OF DAVID GREEN AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln

* Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing Source text: [http://bit.ly/2B3AW23] Further company coverage:

BRIEF-Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system

* Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system for male infertility

BRIEF-Aytu Bioscience CFO Gregory Gould resigns

* Aytu Bioscience Inc - on October 26, 2017, Gregory A. Gould resigned as Chief Financial Officer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up